is exploring how to leverage the value of its extensive data to secure new revenue.The Ann Arbor-based health care IT and consulting services firm is also looking to add five employees for a total of ...

In this free webinar, understand the role of compendia as a bridge between FDA approvals and payer coverage, especially in cases of off-label use, and clarify common misconceptions around off-label ...

February 21, 2009 — Between 50% and 75% of all chemotherapy agents are prescribed off-label. The Centers for Medicare and Medicaid Services (CMS) will pay for off-label usage of cancer drugs but ...

Ann Arbor-based Compendia Bioscience announced a new strategic partnership with San Diego, Calif.-based Althea Diagnostics and the immediate availability of the partnership's first joint product and ...

This weekly column offers opinions on the latest pharmaceutical industry news. In the complicated world of medicine and money, the federal government relies on a handful of privately run directories ...

The compendia used to make coverage determinations for Medicare Part D are inadequate for many dermatologic diseases, a recent investigation has found. Out of more than 200 evidence-based treatments ...

A number of startups are starting to bring the power of the Web to bear on complex masses of biological data. One of the latest is Compendia Bioscience, an Ann Arbor, Mich., computational biotech that ...

Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics ANN ARBOR, Mich. and CAMBRIDGE, Mass., Feb ...

Compendia Bioscience has announced a strategic collaboration with MDS Pharma Services to deliver OncoPredictor, a novel solution for improved cancer drug development. OncoPredictor combines MDS Pharma ...

Life Technologies has announced the acquisition of Compendia Bioscience, a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug ...

Ann Arbor-based Compendia Bioscience Inc. Tuesday announced the award of $1.3 million in SBIR Fast Track funds to incorporate micro-RNA data and analyses into its Oncomine cancer database platform.

In accordance with federal law, the Centers for Medicare and Medicaid Services (CMS) must reimburse cancer drugs used off-label if one of five authorized drug compendia consider such treatment ...